Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 7

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 7
---
 resources available to do so, without any need to amend or expand the scope of the Company's existing licenses.

In addition, our business strategy includes the opportunistic acquisition of other accretive clinical stage life sciences and biotechnology companies. We have not identified any potential acquisitions at this time, nor have we entered into any agreement, letter of intent or other similar document with respect to any proposed acquisition.

For additional information regarding the business of the Company and the regulatory environment in which it operates, please refer to the offering circular under the heading "Our Business."

<div align='center'>- 1 -</div>

Our Strengths

Our key competitive strengths include:

•A senior management team, led by Dr. Raza Bokhari, that has deep experience in medicine and pharmaceutical science as well as a proven track record in business development and entrepreneurship.

•Successful completion of a Phase 1 study of the Product.

•Potential to treat a range of other common non-melanoma skin cancers as well as pre-cancerous lesions.

Summary Risk Factors

Investing in our securities involves risk. Our ability to execute our strategy is also subject to certain risks. The risks described in "Risk Factors" in this offering circular may cause us to not realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the more significant risks include the following:

•our financial results, including our ability to generate earnings and achieve and sustain profitability (as of September 30, 2024, we had an accumulated deficit of approximately US$27.8 million), may vary significantly from forecasts and from period to period;

•the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates

•our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates, our ability to develop, manage and maintain our direct sales and marketing organizations;

•our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing;

•market risks regarding consolidation in the healthcare industry;

•the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines;

•our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

•the fact that product quality issues or product defects may harm our business, any product liability claims; and

•the regulatory, legal and certain operating risks